NCT07166120 Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients
| NCT ID | NCT07166120 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Smoking Cessation |
| Study Type | INTERVENTIONAL |
| Enrollment | 132 participants |
| Start Date | 2025-09-11 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 132 participants in total. It began in 2025-09-11 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the feasibility and preliminary effects of precision tobacco treatment, compared to usual care, on promoting tobacco treatment in oncology patients and providers in the oncology care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This intervention may increase patient receipt of tobacco treatment, patient medication use, and patient smoking abstinence at 6 months.
Eligibility Criteria
Eligibility Criteria for Clinicians: * Clinician from participating oncology/hematology clinic * At least 18 years of age * Can speak and understand English Inclusion Criteria for Patients: * Patient at participating clinic * Age 18-89 years * Current smoking (average cigarettes per day ≥5) * Can speak and understand English * Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline Exclusion Criteria for Patients: * Active use of smoking cessation medication (within the past 30 days) * Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days) * Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy) * Patients who were deemed by the investigator to be ineligible for participation in the trial
Contact & Investigator
Li-Shiun Chen, ScD, M.D., MPH
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT07166120 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07166120 currently recruiting?
Yes, NCT07166120 is actively recruiting participants. Contact the research team at li-shiun@wustl.edu for enrollment information.
Where is the NCT07166120 trial being conducted?
This trial is being conducted at St Louis, United States, St Louis, United States.
Who is sponsoring the NCT07166120 clinical trial?
NCT07166120 is sponsored by Washington University School of Medicine. The principal investigator is Li-Shiun Chen, ScD, M.D., MPH at Washington University School of Medicine. The trial plans to enroll 132 participants.